News

The company submitted a biologics license application (BLA) to the FDA for its pegylated subcutaneous injectable candidate developed for relapsing forms of multiple sclerosis. The BLA application included

Development of the new antibiotics will receive funding through a public-private partnership. For the initial period of 18 months, HHS will provide $40m and around $200m upon the

In its inspection, the federal agency found that the company violated current Good Manufacturing Practice (cGMP) for the manufacture of APIs and the cGMP regulations for finished pharmaceuticals,

Analyzing human genetic changes will also help in identifying chromosomal abnormalities that cause conditions such as bipolar disorder and schizophrenia. The research partnership, which received $1.8m grant from

As part of the MoU, BTI will team up Glyco-MEV laboratory and Agilent to develop new analytical tools and techniques to confirm the safety and effectiveness of these

Studies showed that LipiGesic M provides a safe, highly effective OTC solution to migraine pain and performs better than the prescription migraine medications. LipiGesic M completed the original

The company, which operates in consumer, pharmaceutical and medical devices, and diagnostics segments, has not disclosed the decision so far, as reported by pakistantoday.com. Meanwhile, Johnson & Johnson

The TRAVERSE study is designed to assess the efficacy and safety profile of Pexa-Vec against advanced primary liver cancer in patients failing prior therapy with sorafenib. The primary

Anti Itchbalm that can be safely used on both adults and children will soon be available in the pharmacies and drug stores across the country. The product, with